Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an amino acid boost brain radiation?

NCT ID NCT06328686

Symptom relief Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tests whether giving the amino acid arginine alongside whole brain radiation is safe and how best to give it (by mouth or IV). Ten adults with cancer that has spread to the brain will receive arginine daily during their 10-day radiation course. The goal is to find the dose that gets the most arginine into the blood, which may help the radiation work better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Arginine (an amino acid supplement)
What this could lead to
If it works, this could point toward a way to make radiation therapy more effective for brain metastases.
What could go wrong
This is a very early, small trial with only 10 participants. It is testing safety and dosing, not yet whether it actually helps. The results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of brain metastases from any primary cancer * Planned to undergo whole-brain radiation therapy (Hippocampal avoidant is ok) * No systemic anti-neoplastic agent concurrent with WBRT (memantine is ok) * Not inpatient at the time of treatment start * Age 18 or older * Able to consent for self Exclusion Criteria: * Patient unwilling/unable to receive daily arginine treatment (IV or oral) for the 10 days of WBRT * Systemic therapy continuing during WBRT * Creatinine \> 1.5 x the upper limit of normal * Alanine aminotransferase (ALT) \> 6x the upper limit of normal * Patient planned to be treated as an inpatient * Age \< 18 years * Adult not able to consent for self * Pregnant * Prisoners * Cognitively impaired/impaired decision-making capacity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic malignant neoplasm in the brain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm metastatic malignant neoplasm in the brain Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic malignant neoplasm in the brain Metastatic malignant solid neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.